Exhibit 5.0
                                 March 28, 1996



Cytogen Corporation
600 College Road East
Princeton, New Jersey 08540

     Re:  Form S-3 Registration Statement
          -------------------------------


Ladies and Gentlemen:

          We have acted as counsel to Cytogen Corporation, a Delaware
corporation (the "Company"), in connection with the preparation and filing of a
Registration Statement on Form S-3 (the "Registration Statement") being filed
today with the Securities and Exchange Commission under the Securities Act of
1933, as amended (the "Securities Act"), relating to the offer and sale from
time to time pursuant to Rule 415 of the Securities Act of up to 5,000,000
shares (the "Shares") of Cytogen's Common Stock, par value $.01 per share.

          In that connection, we have examined originals, or copies certified or
otherwise identified to our satisfaction, of such documents, corporate records
and other instruments as we have deemed necessary for the purposes of this
opinion, including the following: (a) the Certificate of Incorporation of the
Company, as amended; and (b) the By-laws of the Company filed as Exhibits to the
Registration Statement.

          In rendering this opinion, we have assumed that (a) the Registration
Statement and any amendments thereto (including post-effective amendments) will
have become effective and comply with all applicable laws; (b) the Registration
Statement will be effective and will comply with all applicable laws at the time
the Shares are offered or issued as contemplated by the Registration Statement;
(c) a Prospectus Supplement will have been prepared and filed with the
Securities and Exchange Commission describing the Shares offered thereby and
will comply with all applicable laws; (d) all Shares will be issued and sold in
compliance with applicable federal and state securities laws and in the manner
stated in the Registration Statement and the appropriate Prospectus Supplement
thereto; and (e) a definitive purchase, underwriting or similar agreement with
respect to any Shares offered or issued will have been duly authorized and
validly executed and delivered by Cytogen and the other parties thereto.

          Based upon and subject to the foregoing, we are of the opinion that
the Shares, when both (a) the Board of Directors of Cytogen has taken all
necessary corporate action to approve the issuance of and the terms of the
offering of the Shares and related matters and (b) certificates representing the
Shares have been duly executed, countersigned, registered and delivered in
accordance with the applicable definitive purchase, underwriting or similar
agreement approved by the Board upon payment of the consideration therefor (not
less than the par value of the Common Stock) provided for therein, will be
legally and validly issued, fully paid and non-assessable.

          We hereby consent to the filing of this opinion as Exhibit 5.0 to the
Registration Statement and to the use of our name in the Prospectus portion
thereof and any Prospectus Supplement thereto, under the caption "Legal
Matters."


                                    Very truly yours,

                                    DECHERT PRICE & RHOADS